Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of LG-0317 in Healthy Chinese Participants
NCT07522970Phase 1Recruiting
- Sponsor
- Lingang Laboratory
- Start
- Apr 2026
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial comparing LG-0317 with Placebo (2 arms). Primary endpoints: Number of participants experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs), Number of participants with clinically significant laboratory assessment abnormalities and 3 more. Started Apr 2026; status: recruiting.
02
Drugs
LG-0317
Beyond the preview
Go deeper on NCT07522970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07522970.